Adagene Inc (ADAG)

Currency in USD
3.590
+0.010(+0.28%)
Closed·
3.5900.000(0.00%)
·
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.3053.670
52 wk Range
1.3004.850
Key Statistics
Prev. Close
3.58
Open
3.55
Day's Range
3.305-3.67
52 wk Range
1.3-4.85
Volume
249.59K
Average Volume (3m)
226.73K
1-Year Change
105.1429%
Book Value / Share
0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADAG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.400
Upside
+161.84%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Adagene Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.400
(+161.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy10.00+178.55%-Maintain14-07-2026
H.C. Wainwright
Buy7.00+94.99%-Maintain07-04-2026
Guggenheim
Buy10.00+178.55%9.00Maintain06-04-2026
Leerink Partners
Buy8.00+122.84%7.00Maintain02-04-2026
Guggenheim
Buy9.00+150.70%-New Coverage24-11-2025

Earnings

Latest Release
03-06-2026
EPS / Forecast
-0.10 / -0.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ADAG Income Statement

Compare ADAG to Peers and Sector

Metrics to compare
ADAG
Peers
Sector
Relationship
P/E Ratio
−13.5x−6.3x−0.4x
PEG Ratio
−0.27−0.100.00
Price/Book
6.7x2.1x2.6x
Price / LTM Sales
30.9x18.5x3.0x
Upside (Analyst Target)
122.8%90.5%50.8%
Fair Value Upside
Unlock9.5%9.4%Unlock

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
162.15K0.25%582.13K
Other Institutional Investors
52.09M78.83%186.99M
Public Companies & Retail Investors
13.82M20.92%49.63M
Total
66.07M100.00%237.2M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Han 2020 Irrevocable Trust11.37%75,12,35126,969
Janus Henderson Group Ltd.10.09%66,66,66623,933

FAQ

What Is the Adagene (ADAG) Share Price Today?

The Adagene share price today is 3.590.

What is the current Adagene (ADAG) share price and day range?

As of 18-07-2026, the Adagene share price is 3.590, with a previous close of 3.580. The share price has ranged from 3.305 to 3.670 today, while the 52-week range spans from 1.300 to 4.850.

What Is the Adagene Market Cap?

As of today, Adagene market cap is 237.200M.

What Is the Adagene (ADAG) Share Price Target?

The average 12-month share price target for Adagene is 9.400, with a high estimate of 14 and a low estimate of 7. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +161.84% Upside potential.

What Is Adagene's Earnings Per Share (TTM)?

The Adagene EPS (TTM) is -0.375.

When Is the Next Adagene Earnings Date?

Adagene will release its next earnings report on 02-09-2026.

From a Technical Analysis Perspective, Is ADAG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Adagene Trade On?

Adagene is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Adagene?

The stock symbol for Adagene is "ADAG."

How Many Times Has Adagene Stock Split?

Adagene has split 0 times.

How Many Employees Does Adagene Have?

Adagene has 128 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.